CDIO Stock Analysis: Buy, Sell, or Hold?
CDIO - Cardio Diagnostics Holdings Inc. Common stock
$2.03
-0.18 (-8.14%)
▼
5d:
-0.49%
30d:
+24.55%
90d:
+34.44%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When CDIO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: CDIO shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: CDIO shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: CDIO is currently trading at $2.03, which is considered extended relative to its 30-day fair value range of $1.59 to $1.96.
Technical Outlook: Technically, CDIO is showing sideways momentum. Immediate support is located at $1.58, while resistance sits at $2.34. Short-term momentum is weak, with the stock down 8.1% recently.
Market Sentiment: CDIO scores 3/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $60.00 (+2855.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CDIO is showing sideways momentum. Immediate support is located at $1.58, while resistance sits at $2.34. Short-term momentum is weak, with the stock down 8.1% recently.
Market Sentiment: CDIO scores 3/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $60.00 (+2855.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.59 -
$1.96
Company Quality Score
32/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
21.1%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (3/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-8.1%)
- BULLISH: Trading 2855.7% below Wall St target ($60.00)
- WARNING: Composite score 32/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.59 -
$1.96
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.58
Resistance Level
$2.34
Current Trend
Sideways
Technical data as of
Aug 21, 2026
Fundamental Context
Wall Street Target
$60.00
(+2855.7%)
Revenue Growth (YoY)
-28.3%
Share & Embed Analysis
Last updated: August 22, 2026 11:49 AM ET
Data refreshes hourly during market hours. Next update: 12:49 PM
Data refreshes hourly during market hours. Next update: 12:49 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CDIO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 33 SELL |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1100 | 43 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 39 SELL |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 26 SELL |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$29 | 49 HOLD |
